Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease (COMPLETE-2)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05701358|
Recruitment Status : Not yet recruiting
First Posted : January 27, 2023
Last Update Posted : January 27, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
COMPLETE-2 is a prospective, multi-centre, randomized controlled trial comparing a strategy of physiology-guided complete revascularization to angiography-guided complete revascularization in patients with acute ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel coronary artery disease (CAD) who have undergone successful culprit lesion Percutaneous Coronary Intervention (PCI).
COMPLETE-2 OCT is a large scale, prospective, multi-centre, observational, imaging study of patients with STEMI or NSTEMI and multivessel CAD in a subset of eligible COMPLETE-2 patients.
|Condition or disease||Intervention/treatment||Phase|
|Acute Myocardial Infarction Coronary Artery Disease||Procedure: Physiology-guided NCL PCI Procedure: Angiography-guided NCL PCI||Not Applicable|
COMPLETE-2 STUDY OBJECTIVES
- To determine whether a strategy of physiology-guided complete revascularization is non-inferior to a strategy of angiography-guided complete revascularization on the efficacy composite outcome of cardiovascular (CV) death, new myocardial infarction (MI) or ischemia-driven revascularization (IDR).
- To determine whether a physiology-guided complete revascularization strategy is superior to an angiography-guided complete revascularization strategy in reducing the safety composite outcome of clinically significant bleeding, stroke, stent thrombosis or contrast-associated acute kidney injury.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||5100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||A Randomized Trial of Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization Strategies & an Observational Study of Optical Coherence Tomography in Patients With Acute MI & Multivessel Coronary Artery Disease|
|Estimated Study Start Date :||March 2023|
|Estimated Primary Completion Date :||March 2028|
|Estimated Study Completion Date :||March 2028|
Active Comparator: Physiology-guided Non-Culprit-Lesion (NCL) PCI
Patients randomized to this group will have their physiology assessment using RFR and/or FFR of all qualifying NCLs that were identified prior to randomization. Other validated non-hyperemic physiology ratios (eg. iFR) may only be used when RFR is not available.
Procedure: Physiology-guided NCL PCI
For RFR, PCI will be performed as per local practice for all lesions with RFR ≤0.89. For FFR, PCI will be performed as per local practice for all NCLs with FFR ≤0.80.
Angiography-guided NCL PCI
Patients randomized to this group will undergo routine staged PCI of all qualifying NCLs that were identified prior to randomization.
Procedure: Angiography-guided NCL PCI
PCI will be performed as per local practice
- Efficacy: Time to first occurrence of the composite of CV death, new MI, or IDR [ Time Frame: at study completion, a minimum of 2 years ]
- Safety: Time to first occurrence of the composite of clinically significant bleeding, stroke, stent thrombosis, or contrast-associated acute kidney injury. [ Time Frame: at study completion, a minimum of 2 years ]
- Time to first occurrence of the composite of CV death or new MI. [ Time Frame: at study completion, a minimum of 2 years ]
- Net clinical outcome: Time to first occurrence of the composite of CV death, new MI, clinically significant bleeding, stroke, stent thrombosis or contrast-associated acute kidney injury. [ Time Frame: at study completion, a minimum of 2 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Patients presenting with STEMI or type 1 NSTEMI and within 72 hours of successful culprit-lesion PCI
Residual coronary artery disease defined as at least 1 additional non-infarct-related coronary artery stenosis that meets all of the following criteria:
- Amenable to successful treatment with PCI
- At least 50% diameter stenosis by visual estimation
- At least 2.5 mm in diameter
- Planned complete revascularization strategy for qualifying MI
- Planned or prior coronary artery bypass graft (CABG) surgery
- Inability to clearly identify a culprit lesion for STEMI or NSTEMI based on angiographic appearance and/or ECG changes and/or regional wall motion abnormalities
- Prior PCI of a non-culprit lesion in a different vessel from the culprit lesion within 45 days of randomization
- Planned medical treatment of all qualifying non-culprit lesions (i.e., no PCI)
- Presence of severe non-culprit-lesion stenosis with reduced epicardial flow (TIMI flow ≤ 2) or >90% visual diameter stenosis
- Presence of a chronic total occlusion (CTO) if it is the only qualifying non-culprit lesion (patients with a CTO plus additional qualifying non-culprit lesions are eligible)
- The only qualifying non-culprit lesion is in the same vessel territory as the culprit lesion
- Baseline STEMI or NSTEMI was due to a suspected non-atherothrombotic mechanism such as type 2 MI (supply-demand mismatch), including spontaneous coronary artery dissection or coronary artery embolism
- Non-cardiovascular co-morbidity with expected life expectancy <2 years
- Any other medical, geographic, or social factor making study participation impractical or precluding 5 year follow-up
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05701358
|Contact: Shamir Mehta, MD||(905) email@example.com|
|Principal Investigator:||Shamir Mehta, MD||Population Health Research Institute|
|Responsible Party:||Population Health Research Institute|
|Other Study ID Numbers:||
|First Posted:||January 27, 2023 Key Record Dates|
|Last Update Posted:||January 27, 2023|
|Last Verified:||January 2023|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
optical coherence tomography
percutaneous coronary intervention
Coronary Artery Disease
Arterial Occlusive Diseases